Team Blog


  • We’ve cloned Brennan

    We’ve experimented with human cloning at this week’s RDD Europe event in Berlin (see picture)

  • Today is World Lupus Day

    Lupus affects at least five million people worldwide, and this figure would probably be higher if the condition wasn’t so notoriously difficult to diagnose…

Similar People


Kate Penn, Project Administrator

Kate Penn
Project Administrator

Read more

Kate joined Team at the beginning of 2012 to provide essential project administration and office management support…

Oliver Harvey, Engineering Consultant

Oliver Harvey
Engineering Consultant

Read more

Oliver is responsible for maintaining robust mechanical design throughout all stages of product development. Oliver has a strong

Occoris_inhaler_concept

Team Consulting receives Technology Strategy Board grant to develop ground-breaking Occoris inhaler

Team Consulting has been awarded a feasibility grant by the Technology Strategy Board, the UK’s innovation agency, to further test the commercial manufacturability of its innovative Occoris™ inhaler ‘engine’ technology. Team’s Occoris technology could potentially open up a wide range of new opportunities in the pulmonary drug delivery sector beyond the traditional asthma and COPD market.
David Harris, Principal Consultant

Polarised trends at RDD 2012

Some 600 delegates braved the heat of the Arizona desert to attend the...
prohaler_150x150

New Inhaler Delivers Simplicity with Enhanced Drug Delivery Performance

A new Dry Powder Inhaler (DPI), designed and developed by Valois Pharma with the support of Team Consulting, was presented for the first time at the recent Drug Delivery to the Lungs Conference in Edinburgh. Whilst offering excellent delivery performance, the Prohaler™ was designed from the outset with the user in mind and is completely intuitive to use.

Team and Valois Pharmaceutical Division partner on new dry powder inhaler development

Team Consulting and Valois Pharmaceutical Division today announced they have embarked upon a major development programme to produce a novel breath-actuated multi-dose Dry Powder Inhaler (DPI). The 'Bead Inhaler' will utilise a unique dispersion technology proven to deliver excellent aerosolisation performance, reproducible emitted dose and high fine particle fraction. A novel drug storage and release technology is also being developed. In addition to offering excellent delivery performance and moisture protection with a wide range of formulations, the inhaler will be compact and simple to use.